

13372 COMPETITIVE PROBLEMS IN THE DRUG INDUSTRY

TABLE A.6.2.—UGDP DATA: ESTIMATES OF THE COEFFICIENTS, THEIR STANDARD DEVIATIONS AND T¹ FOR THE LOGISTIC REGRESSIONS USING ALL VARIABLES

Variable	Coefficient	Standard deviation	T
Age.....	0.0692	0.0213	3.25
Sex.....	-.3956	.3919	-1.01
Race.....	-.6432	.4560	-1.41
Relative weight.....	-1.1122	.7768	-1.43
Blood pressure Systolic.....	.0143	.0076	1.89
Diastolic.....	-.0125	.0154	-.81
Digitalis use by history.....	-.6748	.5117	-1.32
Angina by history.....	-.6519	.5171	-1.26
Abnormal ECG.....	1.3907	.5693	2.44
Cholesterol.....	.0041	.0026	1.58
Arterial calcification.....	.2750	.1877	1.47
Glucose tolerance test.....	.0011	.0031	.36
Serum creatinine.....	.6990	.8727	.80
Visual acuity.....	-.1592	.6095	-.26
Boston.....	1.3005	1.2477	1.04
Minneapolis.....	1.5444	1.1989	1.29
New York.....	.8680	1.3323	.65
Williamson.....	1.0567	1.2473	.85
Cincinnati.....	2.3536	1.3089	1.80
Cleveland.....	.8507	1.4507	.59
Baltimore.....	-.1780	1.6263	-.11
Birmingham.....	.6587	1.3571	.49
Chicago.....	1.1578	1.3484	.86
St. Louis.....	.4500	1.5386	.29
San Juan.....	.3470	1.5304	.23
Time.....	.4362	1.1805	2.42
Tolbutamide.....	1.2412	.4470	2.78
Insulin:			
Standard dose.....	.2424	.4939	.49
Variable dose.....	-.0005	.5257	-.001
Constant.....	-8.8522	2.9440	-3.01

¹ Estimate divided by standard deviation.

TABLE A.6.4.—UGDP DATA: NUMBER OF CARDIOVASCULAR DEATHS OBSERVED AND PREDICTED FROM THE LOGISTIC MODEL

	Treatment			
	Placebo	Tolbutamide	Standard dose insulin	Variable dose insulin
Males:				
≤53:				
Observed.....	1	5	0	1
Expected.....	0.521	2.600	0.952	0.447
>53:				
Observed.....	6	6	5	1
Expected.....	3.640	9.310	4.398	3.130
Total:				
Observed.....	7	11	5	2
Expected.....	4.162	11.910	5.350	3.577
Females:				
≤53:				
Observed.....	1	1	1	1
Expected.....	0.898	3.260	1.107	1.057
>53:				
Observed.....	2	14	7	9
Expected.....	4.940	10.829	6.543	7.365
Total:				
Observed.....	3	15	8	10
Expected.....	5.838	14.088	7.649	8.422